Clinical Topics & News

Should Coal Tar Products Carry Cancer Warnings?

This article addresses the controversy whether over-the-counter products that contain coal tar concentrations greater than 0.5% must carry cancer warnings. Evidence that topical coal tar is carcinogenic in laboratory animals and humans is reviewed. In addition, the potential risk of internal malignancies arising from the topical use of coal tar is discussed. The view is expressed that the California court decision that such products should carry cancer warnings is correct.


 

Recommended Reading

Tipping the Scales: Biologic Therapy 2002 [editorial]
MDedge Dermatology
Patients With Psoriasis Prefer Solution and Foam Vehicles: A Quantitative Assessment of Vehicle Preference
MDedge Dermatology
Trachyonychia: A Case Report and Review of Manifestations, Associations, and Treatments
MDedge Dermatology
Biologic Therapy for Psoriasis: The Tumor Necrosis Factor Inhibitors—Infliximab and Etanercept
MDedge Dermatology
Biologic Therapy for Psoriasis: The T-Cell–Targeted Therapies—Efalizumab and Alefacept
MDedge Dermatology
Stress in a Case of SAPHO Syndrome
MDedge Dermatology
Epidemiology of Skin Diseases in People of Color
MDedge Dermatology
Picking Apart the Picker: A Clinician's Guide for Management of the Patient Presenting With Excoriations
MDedge Dermatology
Successful Treatment of Recalcitrant Palmoplantar Psoriasis With Etanercept
MDedge Dermatology
The Köbner Phenomenon and Psoriatic Arthritis
MDedge Dermatology